Table 2 Main pathological data of the study population.
From: COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City
Parameters | Total (N = 68) | Parameters | Total (N = 68) |
|---|---|---|---|
Airways | Other lesions | ||
Tracheobronchial inflammation, n (%) | Number of other pathological lesions detected, n (%) | ||
Acute, diffuse | 24 (35%) | Absent | 27 (40%) |
Acute, focal | 8 (12%) | 1 | 31 (45%) |
Chronic, diffuse | 28 (41%) | 2 | 8 (12%) |
Chronic, focal | 0 | ≥3 | 2 (3%) |
Absent | 4 (6%) | ||
Not available | 4 (6%) | ||
Alveolar space | Alveolar wall | ||
Acute inflammation, n (%) | Acute inflammation, n (%) | ||
Present, diffuse | 18 (27%) | Present, diffuse | 29 (43%) |
Present, focal | 11 (16%) | Present, focal | 5 (7%) |
Absent | 39 (57%) | Absent | 34 (50%) |
Chronic inflammation, n (%) | Chronic inflammation, n (%) | ||
Present, diffuse | 55 (81%) | Present, diffuse | 59 (87%) |
Present, focal | 8 (12%) | Present, focal | 6 (9%) |
Absent | 5 (7%) | Absent | 3 (4%) |
Hyaline membranes, n (%) | Pneumocyte type II hyperplasia with interstitial fibroblasts, n (%) | ||
Present, diffuse | 42 (61.8%) | Present, diffuse | 17 (25%) |
Present, focal | 17 (25%) | Present, focal | 7 (10%) |
Absent | 9 (13.2%) | Absent | 44 (65%) |
Pneumocyte type II hyperplasia, n (%) | |||
Present, diffuse | 37 (54.4%) | Vessels | |
Present, focal | 9 (13.2%) | Microthrombi, n (%) | 44 (65%) |
Absent | 22 (32.4%) | Present, diffuse | 13 (19%) |
Present, focal | 11 (16%) | ||
Absent | |||
Organizing Pneumonia, n (%) | |||
Present, diffuse | 11 (16%) | Large thrombi, n (%) | 22 (32%) |
Present, focal | 12 (18%) | Present, diffuse | 7 (10%) |
Absent | 45 (66%) | Present, focal | 39 (58%) |
Absent | |||
